|
"楊志新"的相關文件
顯示項目 51-60 / 209 (共21頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
| 國立臺灣大學 |
2015 |
AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases.
|
Kim, Dong-Wan; Yang, James Chih-Hsin; Chen, Kan; Cheng, Ziqiang; Yin, Lucy; Martin, Paul David; Yang, Zhenfan; Jiang, Haiyi; Ahn, Myung-Ju; 楊志新 |
| 國立臺灣大學 |
2015 |
TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy.
|
Yang, James Chih-Hsin; Popat, Sanjay; Georgiou, Panos; Miyamoto, Emiko; Isaacson, Jeffrey D.; Wakelee, Heather A.; 楊志新 |
| 國立臺灣大學 |
2015 |
The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia
|
Kuo, Hung-Yang; Lin, Zhong-Zhe; Kuo, Raymond; Shau, Wen-Yi; Lai, Chiu-Lin; Yang, Yen-Yun; Shao, Yu-Yun; Hsu, Chiun; Cheng, Wen-Fan; Cheng, Ann-Lii; Yang, James Chih-Hsin; Lai, Mei-Shu; 郭漢岳; 郭弘揚; 鄭文芳; 楊志新; 邵幼雲; 賴美淑; 林宗哲; 鄭安理; 許駿 |
| 國立臺灣大學 |
2015 |
The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases
|
Chiang, Yun; Yang, James Chih-Hsin; Hsu, Feng-Ming; Chen, Yu-Hsuan; Shih, Jin-Yuan; Lin, Zhong-Zhe; Lan, Keng-Hsueh; Cheng, Ann-Lii; Kuo, Sung-Hsin; 楊志新; 郭頌鑫; 鄭安理; 陳育瑄; 藍耿學; 施金元; 許峰銘 |
| 國立臺灣大學 |
2015 |
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer
|
Liao, Bin-Chi; Lin, Chia-Chi; Yang, James Chih-Hsin; 林家齊; 楊志新; 廖斌志 |
| 國立臺灣大學 |
2015 |
The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials.
|
Lee, Chee; Davies, Lucy Claire; Wu, Yi-Long; Mitsudomi, Tetsuya; Inoue, Akira; Rosell, Rafael; Zhou, Caicun; Nakagawa, Kazuhiko; Throngprasert, Sumitra; Fukuoka, Masahiro; Gralla, Richard J.; Gebski, Val; Mok, Tony; Yang, James Chih-Hsin; 楊志新 |
| 國立臺灣大學 |
2015 |
Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy
|
Liao, Bin-Chi; Lin, Chia-Chi; Shih, Jin-Yuan; Yang, James Chih-Hsin; 林家齊; 楊志新; 廖斌志; 施金元 |
| 國立臺灣大學 |
2015 |
Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.
|
Papadimitrakopoulou, Vassiliki; Patnaik, Amita; Borghaei, Hossein; Stevenson, James; Gandhi, Leena; Gubens, Matthew A.; Yang, James Chih-Hsin; Sequist, Lecia V.; Ge, Joy Yang; Bourque, Jennifer; Bachman, Robert D.; Im, Ellie; Gadgeel, Shirish M.; 楊志新 |
| 國立臺灣大學 |
2015 |
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
|
Soria, Jean-Charles; Wu, Yi-Long; Nakagawa, Kazuhiko; Kim, Sang-We; Yang, Jin-Ji; Ahn, Myung-Ju; Wang, Jie; Yang, James Chih-Hsin; Lu, You; Atagi, Shinji; Ponce, Santiago; Lee, Dae Ho; Liu, Yunpeng; Yoh, Kiyotaka; Zhou, Jian-Ying; Shi, Xiaojin; Webster, Alan; Jiang, Haiyi; Mok, Tony S. K.; 楊志新 |
| 國立臺灣大學 |
2015 |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis
|
Liao, Bin-Chi; Lee, Jih-Hsiang; Lin, Chia-Chi; Chen, Ya-Fang; Chang, Chin-Hao; Ho, Chao-Chi; Shih, Jin-Yuan; Yu, Chong-Jen; Yang, James Chih-Hsin; 林家齊; 楊志新; 廖斌志; 陳雅芳; 余忠仁; 何肇基; 施金元; 李日翔; 張晉豪 |
顯示項目 51-60 / 209 (共21頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目
|
